Author Topic: GUD.V - Knight Therapeutics  (Read 32463 times)

wisowis

  • Full Member
  • ***
  • Posts: 114
Re: GUD.V - Knight Therapeutics
« Reply #80 on: September 08, 2019, 10:44:58 AM »
Looks like they bought back ~4.6 million shares in July, or ~3% of the company.

I have a stupid question. Their NCIB says "[the company] may purchase up to a daily maximum of 88,853 Shares". Their Q2 update said "The NCIB commenced on July 11, 2019...As at August 6, 2019, the Company has purchased 4,657,235 common shares." Obviously this is well above 88k shares per trading day. I have also noticed they have been buying some large blocks, over 1 million shares in a day.

This seems to be contrary to the NCIB - are they allowed to do this? What are the rules governing it?

Thanks.


no_free_lunch

  • Hero Member
  • *****
  • Posts: 1523
Re: GUD.V - Knight Therapeutics
« Reply #81 on: October 08, 2019, 08:47:36 PM »
Just finally catching up on this one.

Thanks for your posts snowball, NERLYNX was a good find.  I don't know the exact number but it has significant potential.

I did 5 minutes of google work and found this on it.  The article references NERLYNX as neratinib but it's the same product.  It's not smoke, the product really works.

Quote
Results at 2 years of follow-up showed that treatment with neratinib led to a 51% reduction in the risk invasive disease recurrence or death at 2 years compared with placebo.

https://www.targetedonc.com/news/health-canada-approves-extended-adjuvant-neratinib-for-earlystage-hr-breast-cancer

snowball82

  • Sr. Member
  • ****
  • Posts: 334
Re: GUD.V - Knight Therapeutics
« Reply #82 on: October 09, 2019, 02:29:04 AM »
Just finally catching up on this one.

Thanks for your posts snowball, NERLYNX was a good find.  I don't know the exact number but it has significant potential.

I did 5 minutes of google work and found this on it.  The article references NERLYNX as neratinib but it's the same product.  It's not smoke, the product really works.

Quote
Results at 2 years of follow-up showed that treatment with neratinib led to a 51% reduction in the risk invasive disease recurrence or death at 2 years compared with placebo.

https://www.targetedonc.com/news/health-canada-approves-extended-adjuvant-neratinib-for-earlystage-hr-breast-cancer

Welcome, GUD seems also interested by shopping in Latin America

https://www.grupobiotoscana.com/en/

 https://braziljournal.com/eurofarma-e-knight-therapeutics-disputam-a-biotoscana